Impact of I1307K APC Polymorphism on Breast Cancer
Author Information
Author(s): Yuan Z Q, Bégin L R, Wong N, Brunet J-S, Trifiro M, Gordon P H, Pinsky L, Foulkes W D
Primary Institution: Sir MB Davis-Jewish General Hospital
Hypothesis
Does the I1307K APC polymorphism affect the clinicopathological features and prognosis of breast cancer?
Conclusion
The I1307K polymorphism does not appear to be associated with any specific features of breast cancer or affect prognosis.
Supporting Evidence
- Twenty-four of 209 cases (11.5%) were found to carry the I1307K polymorphism.
- No association was observed between the polymorphism and age at diagnosis, grade, tumour size, lymph node status, oestrogen receptor status, or P53 immunoreactivity.
- The 5-year survival for women with the I1307K polymorphism was 88.9% compared to 81.6% for those without.
Takeaway
This study looked at a gene change in women with breast cancer and found it doesn't really change how the cancer behaves or how well people do.
Methodology
Genotyping of paraffin-embedded breast cancers and analysis of clinicopathological correlations.
Limitations
The study only included Ashkenazi Jewish women diagnosed below the age of 65.
Participant Demographics
Ashkenazi Jewish women diagnosed with breast cancer below the age of 65.
Statistical Information
P-Value
P = 0.34
Confidence Interval
95% confidence interval 7.5–16.6
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website